Spray a spray to prevent the flu. The FDA approved the Astrazeneca PLC Sponsored ADR (AZN.US) FluMist vaccine.

The US FDA has approved FluMist, a needle-free nasal spray developed by Astrazeneca PLC Sponsored ADR (AstraZeneca, AZN.US), for the prevention of flu caused by type A and type B influenza viruses in individuals aged 2 to 49 years old. FluMist is the first flu vaccine that can be self-administered by eligible patients or administered by caregivers. FluMist is a live attenuated vaccine administered in the form of a nasal spray to prevent the flu. The vaccine was initially approved in the US in 2003 for use in children and adults aged 5 to 49, setting an important precedent for the development of intranasal vaccines and demonstrating the protective role of mucosal immune response. FluMist is also one of the flu vaccines recommended by the US Advisory Committee on Immunization Practices (ACIP) and the American Academy of Pediatrics (AAP). In 2007, the US FDA further approved the use of FluMist in children aged 2 to 5 years old.